BioXcel Therapeutics, Inc. has announced that its development program for BXCL701, a combination treatment with a checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer, has been accelerated through a Fast Track designation by the FDA. This treatment is specifically intended for patients who have progressed on chemotherapy and show no evidence of microsatellite instability.
Vincent O'Neill, a senior officer at BioXcel Therapeutics overseeing Product Development and Medical matters, commented that the positive survival outcomes from the Phase 2 trial, reported at the end of last year, encouraged the company. They look forward to engaging in further dialogues about the registration pathway at upcoming meetings with the FDA.
In the stock market, BioXcel Therapeutics' shares rose by 14% in pre-market trading on Monday.
You can read similar health news on the RTT News website.
